Menu
Warfarin is indicated for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.
it is indicated for the prophylaxis after insertion of prosthetic heart valves.
it is indicated for the prophylaxis and treatment of venous thrombosis and pulmonary embolism.
it is indicated for transient cerebral ischaemic attacks.
Adults and elderly patients: The typical induction dose of this tablet is 10 mg daily for 2 days, but this should be tailored to individual requirements. Baseline prothrombin measurements (PT) should be taken before beginning therapy with this tablet.
The daily maintenance dose of This tablets is usually 3 to 9 mg taken at the same time each day. The exact maintenance dose for an individual is dependent on the prothrombin time or other appropriate coagulation tests. The maintenance dose is omitted if the prothrombin time is excessively prolonged. Once the maintenance dose is stabilised in the therapeutic range, it is rarely necessary to alter it.
In emergencies, anticoagulant therapy should be initiated with heparin and warfarin together. Where there is less urgency, as in patients disposed to or at special risk of thromboembolism, anticoagulant therapy may be initiated alone.
Concomitant heparin therapy affects the results of control tests and should be discontinued at least six hours before the first test is carried out.
Control is established with INR monitoring at regular intervals and subsequent it is maintenance dosage further adjusted according to the results obtained.
Paediatric population: No data are available.
Infections and infestations
Fever
Immune system disorders
Hypersensitivity
Nervous system disorders
Cerebral haemorrhage; Cerebral subdural haematoma
Vascular disorders
Haemorrhage
Respiratory, thoracic and mediastinal disorders
Haemothorax, epistaxis
Gastrointestinal disorders
Gastroinestinal haemorrhage, rectal haemorrhage, haematemesis; pancreatitis; diarrhoea; nausea; vomiting; melaena
Hepatobiliary disorders
Jaundice; hepatic dysfunction
Skin and subcutaneous disorders
Rash; alopecia; purpura; ‘purple toes’ syndrome; erythematous swollen skin patches leading to ecchymosis, infarction and skin necrosis; calciphylaxis
Renal and Urinary disorders
Haematuria; anticoagulant-related nephropathy
If a rapid antithrombotic effect is needed, heparin treatment must be initiated first. After this, heparin treatment is continued for at least 5 to 7 days until the INR has been at the target level for at least two days.
Interactions
There is a large risk for interactions when this anticoagulant is used concomitantly with other drugs. Intensified monitoring of the therapeutic response is therefore recommended when treatment with other drugs is initiated or withdrawn.
Genetic variations
Elimination of this anticoagulant is slower in patients with certain mutations in the gene for the enzyme CYP2C9 metabolizing (S)-anticoagulant. These patients only require a low maintenance dose and have a risk of excessive bleeding if a high initial dose is given. It will also take longer to achieve the new efficacy level after adjusting the dose. Additionally, patients with genetic variations of the enzyme VKOR may require lower doses due to increased sensitivity to the drug.
Resistance
Resistance to this anticoagulant is a very rare phenomenon. Only case reports have been published on that. These patients need 5 to 20 times the usual doses to achieve a therapeutic response. If the patient’s response is poor, other more plausible causes should be ruled out: patient noncompliance, interaction with other medications or food, and laboratory errors.
Coumarin necrosis
To avoid coumarin necrosis, patients with a hereditary deficiency of antithrombotic proteins C or S must first be treated with heparin. Loading doses of this anticoagulant must not exceed 5 mg. Heparin treatment must be continued for 5 to 7 days as described above.
Store below 30°C and protect from light and moisture.
Keep out of reach of children.
1 x10 Alu/PVC blister
Tablets BP 5 mg are available in an Alu/PVC blister of 10 tablets. Such 01 blister in a carton with pack insert.
Questions are useful tools, they open lines of communication; give us information; improve interactions, facilitate analysis, and many more.
A pharma CMO is a special kind of an organization, offering contract manufacturing services to pharmaceutical companies for various kinds of drug formulations.
Reduce overall costs and time to market :
Contract manufacturers already have the needed infrastructure and technical staff, so working with a CMO or CDMO can decrease the cost of manufacturing your pharmaceutical products.
Scalability and flexible production capacity :
You can produce what you need when you need it without worrying about excess capacity. Additionally, CMOs understand the importance of quality and compliance, so you don't have to sacrifice safety for scalability.
Save on upgrading and maintaining equipment :
If you have your manufacturing facility, you’ll have to pay to upgrade your equipment as technology advances—which can get expensive. A CMO/CDMO’s only function is to make and distribute products, so part of their core business responsibility is to update their equipment whenever needed and perform maintenance.
Ease supply chain issues :
During the pandemic, there were several instances of supply chain issues, including medicine shortages. CMOs are generally better equipped than startups to handle a supply chain crisis.
Bandwidth to focus on core competencies
When your company resources aren’t directly allocated to manufacturing and distribution, you have more time to focus on other tasks, like marketing your new drug, researching, or working on drug discovery.
We have 7+ manufacturing sites with a minimum of WHO GMP certification and other country-specific approvals like NAFDAC approved, PPK Kenya Approved, TFDA Tanzania Approved, EU-GMP Approved.
We have below manufacturing capacity:
For Tablet, Capsule, and soft gel: up to 1 million units per shift
For Syrup: up to 0.05 Million per shift
For Ampoule and Vial: up to 0.1 million units per shift
For Ointment and Cream: up to 0.1 million units per shift
For Suppository: 0.1 Million units per shift
Contact us directly to receive full information on the product, the formulation, the science behind it, stability data, and more. Our Business Development Manager is a click away.
Conical Pharmaceuticals is a professionally managed and dynamic organization with decades of experience in the pharmaceutical field. With a desire of providing opportunities for a better life, we work very hard to bring quality drugs to our customers. We have instilled a level of trust and confidence amongst our clients by supplying the best quality products.
